Medicamen Biotech , a prominent player in the biotech sector, has announced significant developments following its recent board meeting held on August 12, 2025. The company has approved its unaudited financial results for the quarter ended June 30, 2025, and made key changes to its board composition.

Board Appointments and Changes

In a strategic move to strengthen its leadership, Medicamen Biotech has appointed three new directors:

1. Mr. Ashwani Kumar Sharma has been elevated from his role as Non-Executive Director to Executive Director. His appointment as Whole-time Director is for a period of five years, effective August 12, 2025. Mr. Sharma brings valuable experience in managing supply chain activities from his tenure at Shivalik Rasayan Limited.

2. Mr. Sham Goel joins as a Non-Executive Independent Director. A Chartered Accountant with over 30 years of experience in finance, taxation, and accounts, Mr. Goel's expertise includes financial analysis and taxation matters. He is currently a Director at Essem Logistics Limited.

3. Mr. Shaival Saurabh has been appointed as a Non-Executive Independent Director. With more than 30 years of experience in branding and advertising, Mr. Saurabh has a proven track record in helping both small and large corporates achieve brand growth through effective marketing strategies.

These appointments are subject to shareholder approval and are set for a term of five years each, commencing from August 12, 2025.

Financial Results and Dividend Proposal

The board has approved the unaudited financial results for Q1 FY26 (quarter ended June 30, 2025). While specific financial figures were not disclosed in the announcement, the company noted that the auditors have provided unmodified opinions on the quarterly results, indicating a clean audit report.

In a move that may please shareholders, the board has proposed a final dividend of 10% or Re. 1.00 per equity share for the financial year 2024-25. This proposal will be subject to approval at the upcoming Annual General Meeting (AGM).

Upcoming Annual General Meeting

Medicamen Biotech has scheduled its 32nd AGM for September 26, 2025, at 12:00 noon. In line with modern practices, the meeting will be held through Video Conference (VC) or Other Audio-Visual Means (OAVM).

Key dates related to the AGM include:

The book closure is to facilitate the payment of the final dividend, if approved by shareholders at the AGM.

Conclusion

These developments at Medicamen Biotech, including the board restructuring and the proposed dividend, reflect the company's commitment to strong corporate governance and shareholder value. The addition of experienced professionals to the board is expected to bring fresh perspectives and expertise to guide the company's future growth strategies.

Investors and stakeholders will likely look forward to more detailed financial information and future outlook during the upcoming AGM.

Medicamen Biotech Ltd has marked a significant milestone in its pharmaceutical journey by securing its first Abbreviated New Drug Application (ANDA) approval from the U.S. Food and Drug Administration (USFDA). The approval is for Bortezomib for injection, a notable achievement that could potentially open new avenues for the company in the U.S. pharmaceutical market.

ANDA Approval Details

The USFDA's approval for Bortezomib for injection represents a crucial step forward for Medicamen Biotech. Bortezomib is known for its use in treating multiple myeloma and mantle cell lymphoma, making it an important addition to the company's product portfolio.

Significance of the Approval

This first ANDA approval is being hailed as a significant milestone for Medicamen Biotech. It demonstrates the company's capability to meet the stringent quality and regulatory standards set by the USFDA, which is widely regarded as one of the most demanding regulatory bodies in the global pharmaceutical industry.

Potential Impact

The ANDA approval could have several positive implications for Medicamen Biotech:

1. Market Entry: It paves the way for the company to enter the lucrative U.S. pharmaceutical market with its approved product.
2. Revenue Growth: The approval might potentially lead to increased revenue streams once the product is commercialized in the U.S. market.
3. Enhanced Credibility: Securing USFDA approval enhances the company's credibility in the global pharmaceutical landscape.
4. Future Prospects: This achievement could serve as a stepping stone for future ANDA approvals, expanding the company's product offerings in the U.S. market.

While this approval marks a significant achievement for Medicamen Biotech, investors and stakeholders will likely be keen to see how the company capitalizes on this opportunity and translates it into tangible business growth in the coming quarters.